國立虎尾科技大學 |

Breast Cancer Metastasis and Drug Resistance = Challenges and Progress /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Breast Cancer Metastasis and Drug Resistance/ edited by Aamir Ahmad.
其他題名:	Challenges and Progress /
其他作者:	Ahmad, Aamir.
面頁冊數:	XVIII, 427 p. 60 illus., 51 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-030-20301-6
ISBN:	9783030203016

Breast Cancer Metastasis and Drug Resistance = Challenges and Progress /
Breast Cancer Metastasis and Drug ResistanceChallenges and Progress /[electronic resource] :edited by Aamir Ahmad. - 2nd ed. 2019. - XVIII, 427 p. 60 illus., 51 illus. in color.online resource. - Advances in Experimental Medicine and Biology,11520065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Chaper 1: Breast Cancer Statistics: Recent trends -- Chapter 2: Epidemiology of Breast Cancer in Women -- Chapter 3: Health and Racial Disparity in Breast Cancer -- Chapter 4: Breast Cancer: Current perspectives on the disease status -- Chapter 5: Role of Autophagy in Breast Cancer Development and Progression: Opposite Sides of the Same Coin -- Chapter 6: Breast Cancer Heterogeneity in Primary and Metastatic Disease -- Chapter 7: Bone Metastasis of Breast Cancer -- Chapter 8: Therapeutic Options for Metastatic Breast Cancer -- Chapter 9: Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment -- Chapter 10: Current Updates on Trastuzumab Resistance in HER2 overexpressing Breast Cancers -- Chapter 11: Non-coding RNAs as mediators of tamoxifen resistance in breast cancers -- Chapter 12: TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome Drug Resistance -- Chapter 13: Current state of platinum complexes for the treatment of advanced and drug-resistant breast cancers -- Chapter 14: Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance -- Chapter 15: Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and its Partners to Overcome Metastasis and Drug Resistance -- Chapter 16: Epigenetics of Breast Cancer: Clinical Status of Epi-Drugs and Phytochemicals -- Chapter 17: Targeting CSC in a most aggressive subtype of breast cancer TNBC -- Chapter 18: Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability -- Chapter 19: NEDD4 Family of E3 Ubiquitin Ligases in Breast Cancer: Spotlight on SMURFs, WWPs and NEDD4 -- Chapter 20. Emerging Novel Therapeutics in Triple-Negative Breast Cancer -- Chapter 21.Breast Cancer: Proteolysis and Migration -- Chapter 22: Current and emerging 3D models to study breast cancer.

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

ISBN: 9783030203016

Standard No.: 10.1007/978-3-030-20301-6doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Breast Cancer Metastasis and Drug Resistance = Challenges and Progress /
LDR:04638nam a22004095i 4500 001 1006355
003 DE-He213
005 20200630155151.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030203016 $9 978-3-030-20301-6
024 7 $a 10.1007/978-3-030-20301-6 $2 doi
035 $a 978-3-030-20301-6
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Breast Cancer Metastasis and Drug Resistance $h [electronic resource] : $b Challenges and Progress / $c edited by Aamir Ahmad.
250 $a 2nd ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a XVIII, 427 p. 60 illus., 51 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1152
505 0 $a Chaper 1: Breast Cancer Statistics: Recent trends -- Chapter 2: Epidemiology of Breast Cancer in Women -- Chapter 3: Health and Racial Disparity in Breast Cancer -- Chapter 4: Breast Cancer: Current perspectives on the disease status -- Chapter 5: Role of Autophagy in Breast Cancer Development and Progression: Opposite Sides of the Same Coin -- Chapter 6: Breast Cancer Heterogeneity in Primary and Metastatic Disease -- Chapter 7: Bone Metastasis of Breast Cancer -- Chapter 8: Therapeutic Options for Metastatic Breast Cancer -- Chapter 9: Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment -- Chapter 10: Current Updates on Trastuzumab Resistance in HER2 overexpressing Breast Cancers -- Chapter 11: Non-coding RNAs as mediators of tamoxifen resistance in breast cancers -- Chapter 12: TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome Drug Resistance -- Chapter 13: Current state of platinum complexes for the treatment of advanced and drug-resistant breast cancers -- Chapter 14: Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance -- Chapter 15: Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and its Partners to Overcome Metastasis and Drug Resistance -- Chapter 16: Epigenetics of Breast Cancer: Clinical Status of Epi-Drugs and Phytochemicals -- Chapter 17: Targeting CSC in a most aggressive subtype of breast cancer TNBC -- Chapter 18: Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability -- Chapter 19: NEDD4 Family of E3 Ubiquitin Ligases in Breast Cancer: Spotlight on SMURFs, WWPs and NEDD4 -- Chapter 20. Emerging Novel Therapeutics in Triple-Negative Breast Cancer -- Chapter 21.Breast Cancer: Proteolysis and Migration -- Chapter 22: Current and emerging 3D models to study breast cancer.
520 $a Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.
650 0 $a Cancer research. $3 1253664
650 0 $a Drug resistance. $3 872072
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Ahmad, Aamir. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1072728
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030203009
776 0 8 $i Printed edition: $z 9783030203023
776 0 8 $i Printed edition: $z 9783030203030
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-20301-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)